TNFRSF1B and ischemic stroke: The TNFR2+ classical monocyte population was comparable in controls [11.41% (4.39–39.18)] and ischemic stroke patients [8.49% (4.10–32.86), U = 79.5, p = 0.59] (Figure 3h), but the TNFR2+ non-classical monocyte cells [Ctl: 61.72% (20.02–84.81) and IS: 80.50% (71.51–87.15), U = 52, p = 0.07] and intermediate monocyte cells [Ctl: 31.02% (23.52–37.16) and IS: 39.56% (32.45–55.41), U = 52, p = 0.07] both showed a trend towards an increase in ischemic stroke patients compared to controls (Figure 3h).